GlaxoSmithKline PLC

38.39-0.9500-2.41%Vol 4.30M1Y Perf 2.97%
Sep 24th, 2021 16:00 DELAYED
BID38.31 ASK39.00
Open38.54 Previous Close39.34
Pre-Market- After-Market38.35
 - -  -0.04 -0.10%
Target Price
46.90 
Analyst Rating
Moderate Buy 2.27
Potential %
22.17 
Finscreener Ranking
★★     46.38
Insiders Trans % 3/6/12 mo.
100/100/93 
Value Ranking
★+     43.37
Insiders Value % 3/6/12 mo.
100/100/61 
Growth Ranking
★★     47.27
Insiders Shares Cnt. % 3/6/12 mo.
100/100/62 
Income Ranking
★+     35.36
Price Range Ratio 52W %
54.46 
Earnings Rating
Neutral
Market Cap103.37B 
Earnings Date
27th Oct 2021
Alpha-0.00 Standard Deviation0.05
Beta0.70 

Today's Price Range

38.3738.70

52W Range

33.2642.68

5 Year PE Ratio Range

7.3097.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-1.39%
1 Month
-6.62%
3 Months
-3.49%
6 Months
6.43%
1 Year
2.97%
3 Years
-4.88%
5 Years
-11.58%
10 Years
17.92%

TickerPriceChg.Chg.%
GSK38.39-0.9500-2.41
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Financial StrengthValueIndustryS&P 500US Markets
0.20
0.80
0.57
1.66
7.90
Leverage Ratio 5.30
ProfitabilityValueIndustryS&P 500US Markets
66.30
19.10
32.30
12.40
15.54
RevenueValueIndustryS&P 500US Markets
40.52B
16.11
3.26
4.93
DividendsValueIndustryS&P 500US Markets
5.46
2.12
-0.72
-0.68
Payout ratio76.00
Earnings HistoryEstimateReportedSurprise %
Q02 20210.540.7946.30
Q01 20210.630.630.00
Q04 20200.700.62-11.43
Q03 20200.780.9217.95
Q02 20200.490.48-2.04
Q01 20200.790.9722.78
Q04 20190.680.64-5.88
Q03 20190.830.9514.46
Earnings Per EndEstimateRevision %Trend
9/2021 QR0.80-2.44Negative
12/2021 QR0.63-10.00Negative
12/2021 FY2.802.94Positive
12/2022 FY3.081.65Positive
Next Report Date27th Oct 2021
Estimated EPS Next Report0.80
Estimates Count4
EPS Growth Next 5 Years %6.80
Volume Overview
Volume4.30M
Shares Outstanding2.69B
Shares Float2.51B
Trades Count26.39K
Dollar Volume223.29M
Avg. Volume4.82M
Avg. Weekly Volume4.41M
Avg. Monthly Volume3.60M
Avg. Quarterly Volume3.60M

GlaxoSmithKline PLC (NYSE: GSK) stock closed at 38.39 per share at the end of the most recent trading day (a -2.41% change compared to the prior day closing price) with a volume of 4.36M shares and market capitalization of 103.37B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 99437 people. GlaxoSmithKline PLC CEO is Emma N. Walmsley.

The one-year performance of GlaxoSmithKline PLC stock is 2.97%, while year-to-date (YTD) performance is 4.32%. GSK stock has a five-year performance of -11.58%. Its 52-week range is between 33.26 and 42.68, which gives GSK stock a 52-week price range ratio of 54.46%

GlaxoSmithKline PLC currently has a PE ratio of 15.50, a price-to-book (PB) ratio of 4.60, a price-to-sale (PS) ratio of 2.41, a price to cashflow ratio of 11.20, a PEG ratio of 2.32, a ROA of 5.59%, a ROC of 11.88% and a ROE of 31.09%. The company’s profit margin is 15.54%, its EBITDA margin is 32.30%, and its revenue ttm is $40.52 Billion , which makes it $16.11 revenue per share.

Of the last four earnings reports from GlaxoSmithKline PLC, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.80 for the next earnings report. GlaxoSmithKline PLC’s next earnings report date is 27th Oct 2021.

The consensus rating of Wall Street analysts for GlaxoSmithKline PLC is Moderate Buy (2.27), with a target price of $46.9, which is +22.17% compared to the current price. The earnings rating for GlaxoSmithKline PLC stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

GlaxoSmithKline PLC has a dividend yield of 5.46% with a dividend per share of $2.12 and a payout ratio of 76.00%.

GlaxoSmithKline PLC has a Sell technical analysis rating based on Technical Indicators (ADX : 7.42, ATR14 : 0.51, CCI20 : -119.01, Chaikin Money Flow : -0.21, MACD : -0.53, Money Flow Index : 23.52, ROC : -5.26, RSI : 29.25, STOCH (14,3) : 2.68, STOCH RSI : 0.05, UO : 38.99, Williams %R : -97.32), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of GlaxoSmithKline PLC in the last 12-months were: Charles A. Bancroft (Buy at a value of $128 643), Emma N. Walmsley (Buy at a value of $1 500), Emma N. Walmsley (Sold 32 346 shares of value $391 613 ), Hal V Barron (Buy at a value of $12 067 774), Hal V Barron (Sold 173 710 shares of value $3 100 532 ), Jesse Goodman (Buy at a value of $53 439), Jonathan Richard Symonds (Buy at a value of $569 634), Jonathan Richard Symonds (Sold 17 888 shares of value $235 567 ), Judy C. Lewent (Buy at a value of $55 225), Laurie H. Glimcher (Buy at a value of $162 010), Lynn Laverty Elsenhans (Buy at a value of $76 321), Manvinder Singh Banga (Buy at a value of $539 687), Urs Rohner (Buy at a value of $33 755), Vivienne Cox (Buy at a value of $33 755)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (45.45 %)
5 (45.45 %)
5 (45.45 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
5 (45.45 %)
5 (45.45 %)
5 (45.45 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (9.09 %)
1 (9.09 %)
1 (9.09 %)
Summary RatingModerate Buy
2.27
Moderate Buy
2.27
Moderate Buy
2.27

GlaxoSmithKline PLC

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.

CEO: Emma N. Walmsley

Telephone: +44 2080475000

Address: 980 Great West Road, Brentford TW8 9GS, Middlesex, GB

Number of employees: 99 437

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

64%36%

Bearish Bullish

55%45%

Bearish Bullish

57%43%

TipRanks News for GSK

Mon, 23 Aug 2021 10:32 GMT A Look at 23andMes Earnings and Risk Factors Amid Therapeutic Efforts

- TipRanks. All rights reserved.

News

Stocktwits